INTRODUCTION
Neuroblastoma and Wilms tumor are the two most common extracranial solid tumors in children younger than age 15 years, accounting for approximately 13 .6% of malignancies in the pediatric population [1] . Similarities between these tumors include their embryonal origin, a peak incidence in children younger than 5 years of age, and a predominantly abdominal presentation (65% of neuroblastomas and all Wilms tumors) [2] . However, Wilms tumor is associated with a high rate of cure [3] , while children with highrisk neuroblastoma fare poorly despite intensive therapy [4] . In Wilms tumor, the evolution of therapy has focused on achieving higher cure rates with a minimization of long-term adverse effects. Although there has been a similar focus in children with low or intermediate risk neuroblastoma, treatment of patients with highrisk disease has become increasingly intensified [5] . In prior treatment eras, children with Wilms tumor and low or intermediate risk neuroblastoma were exposed to more aggressive multimodal therapies, including radical surgery, orthovoltage radiation, and chemotherapy. Consequently, long-term survivors of low or intermediate risk neuroblastoma as well as Wilms tumor may experience significant long-term adverse effects.
Although several publications have described the long-term medical complications from Wilms tumor [6] [7] [8] [9] [10] [11] and neuroblastoma [12] [13] [14] [15] [16] [17] [18] [19] , there are few studies describing the healthrelated quality of life (HRQL) of these survivors. Barr and colleagues compared HRQL between survivors of Wilms tumor (stages 2-5) and advanced neuroblastoma (stage 4 and inoperable stage 3) using the Health Utilities Index (HUI) in a cohort of 78 patients, 5 years after completion of their therapy [20] . There was no difference in mean overall HRQL utility scores between the two populations, although survivors of Wilms tumor were more likely to be assessed by their parents as having no disabilities. Survivors of neuroblastoma had a higher frequency of deficits in hearing and speech, which is consistent with the high doses of cisplatin that are typically included in treatment regimens for highrisk disease [21, 22] . In another study of 19 patients receiving therapy for high-risk neuroblastoma, decrements in HRQL were noted during the period immediately following diagnosis and in the first few weeks after bone marrow transplantation [23] ; however, this study did not assess long-term outcomes. The greatest morbidity was observed in the pain, self-care, mobility, and emotion domains.
The goal of the present study was to assess HRQL in long-term survivors of Wilms tumor and neuroblastoma, and to examine the sociodemographic, disease and treatment variables that influence these outcomes. We examined data from the Childhood Cancer Survivor Study (CCSS), a follow-up study of approximately 14,000 long-term survivors of pediatric cancer [24] . This cohort includes a considerably larger group of survivors of Wilms tumor and neuroblastoma and a longer period of follow-up than the abovementioned studies. Our primary a priori hypothesis was that the prevalence of adverse outcomes in HRQL would be higher in survivors of neuroblastoma than in survivors of Wilms tumor.
PATIENTS AND METHODS

Childhood Cancer Survivor Study (CCSS)
The survivors of Wilms tumor and neuroblastoma evaluated in this study are a subset of the 14,370 participants in the CCSS. The methodology of the CCSS and a description of the study participants have been published in detail previously [24] . Briefly, the CCSS is a multi-institutional study aimed at determining the late adverse outcomes following treatment for cancer during childhood or adolescence. The CCSS cohort consists of survivors of childhood cancer who were diagnosed before the age of 21 years between 1970 and 1986, and who were alive at least 5 years from their original diagnosis. At the time of study enrollment (1995-1996 for most participants), a comprehensive baseline questionnaire was completed by the participant (if aged 18 years or older) or his or her parent (if younger than age 18 years), and detailed medical information was abstracted from hospital records. Several subsequent questionnaires have been completed by the study participants, including a questionnaire on quality of life that is the basis for this analysis. The study methodology was approved by the Institutional Review Board of each of the 26 participating institutions and informed consent was obtained from each participant or his or her parent or guardian.
Survivors of Wilms Tumor or Neuroblastoma
Eligibility for this analysis of CCSS participants was limited to those diagnosed with Wilms tumor or neuroblastoma who were aged 18 years or older at the time of the CCSS follow-up questionnaire that was administered in 2002 and 2003. Information regarding HRQL and current sociodemographic status (age at interview, household income, health insurance, education, marital status, employment status) were obtained as part of this follow-up questionnaire. Baseline demographics (gender, race), disease variables (diagnosis, age at diagnosis, location of tumor in neuroblastoma patients), and treatment variables (chemotherapy including alkylating agent score and anthracycline score, surgery including history of laminectomy, laparotomy, nephrectomy or thoracotomy, and radiation field and dose) were abstracted from the CCSS database. These data were also used to determine if participants had a major medical condition. This composite measure was defined as the presence of one or more of seizures, congestive heart failure, myocardial infarction, stroke, cirrhosis, pulmonary disease requiring oxygen, solid organ transplant, second malignancy, amputation, or joint replacement [25] .
Measures of Health-Related Quality of Life
HRQL was assessed with the 36-Item Short Form Health Survey (SF-36). The SF-36 is a widely used and well-validated global HRQL instrument that contains eight individual subscales representing physical, emotional, and social well being [26] . These subscales are physical function, role function-physical (assessing  role limitations caused by physical factors), bodily pain, social  function, mental health, role function-emotional (assessing role  limitations caused by emotional factors) , vitality, and general health. The SF-36 can also be scored as two summary scales, the Physical Component Summary scale (PCS) and the Mental Component Summary scale (MCS). General population norms are available for the subscales and summary scales [27] . Data are normalized and presented as t-scores with a normal population mean score set at 50 with a standard deviation of 10.
Statistical Analysis
Descriptive statistics for the sociodemographic, disease and treatment variables were calculated separately for the Wilms tumor and neuroblastoma survivor groups. Means and standard deviations were calculated for the eight subscales and two summary scales of the SF-36, stratified by diagnosis, sociodemographic variables, and the presence or absence of a major medical condition. Means were compared between the two diagnostic groups and between levels of the sociodemographic variables with two sample t-tests. General linear regression was used to evaluate the association between diagnosis, sociodemographic variables, major medical condition, and each of the HRQL outcomes in adjusted models [28] . Results are reported as means and standard deviations with two-sided P-values.
To determine the diagnostic and treatment characteristics of the survivors who indicated poor HRQL, we dichotomized those patients with complete treatment data into two groups for each SF-36 subscale and summary scale. Individuals who scored lower than 40 (greater than one standard deviation below the mean) on any of the SF-36 subscales or summary scales were considered to have poor HRQL in that domain. Frequencies and percents of poor outcomes on each of the SF-36 subscales and summary scales were calculated separately for Wilms tumor and neuroblastoma survivors by diagnostic and treatment variables, and proportions were compared with Chi-squared tests. Multiple variable unconditional logistic regression was used to evaluate the magnitude of the associations between diagnostic and treatment variables and poor HRQL. Final models were selected using goodness of fit methods and by comparing Chi-squared values between full and reduced models [29] . Results are reported as adjusted odds ratios with 95% confidence intervals. SAS version 9.1 (Cary, N.C.) was used for all analyses. Treatment data were available for 1,019 of the 1,086 patients who completed the HRQL follow-up questionnaire. Diagnosis and treatment characteristics of these survivors are shown in Table II . Survivors of Wilms tumor were more likely than survivors of neuroblastoma to have received either chemotherapy or radiation, to have received an anthracycline, or radiation to the abdomen or pelvis, or to have undergone a nephrectomy. In contrast, survivors of neuroblastoma were more likely than survivors of Wilms tumor to have been followed for a longer period of time from diagnosis, to have been treated with either surgery alone or surgery and radiation (compared to treatment with combined modality therapy that included chemotherapy), to have received an alkylating agent, or radiation to the head, neck or spine, or to have undergone a laminectomy or thoracotomy.
RESULTS
Characteristics of the Study Cohort
HRQL Outcomes
Adjusted mean scores on the PCS and MCS are displayed in Table III by sociodemographic variables and diagnostic category. There was no difference between the Wilms tumor and neuroblastoma survivors on either of the two summary scales. Overall, survivors who were looking for work or unable to work (compared to those employed or not seeking paid work) and those without health insurance (compared to those with health insurance) scored significantly lower on the PCS (indicating decreased HRQL due to poor physical function), while patients aged 18-24 years scored significantly higher on the PCS than those older than age 35 years. On the MCS, both the Wilms tumor (mean ¼ 41.66, SE ¼ 2.19) and neuroblastoma (mean ¼ 42.41, SE ¼ 2.23) groups scored almost one standard deviation below the population mean of 50 (P < 0.0001 for both comparisons). Females (compared to males), Native Americans (compared to those who identified themselves as white), and those with an annual household income less than $20,000 (compared to a household income greater than $100,000) scored significantly lower on the MCS. Table IV demonstrates the adjusted mean SF-36 subscale scores by diagnostic group and sociodemographic variables. As with the two summary scales, there were no differences between the Wilms tumor and neuroblastoma survivors on any of the eight subscales. Females scored significantly lower than males on all of the subscales except for bodily pain. Physical function scores were lower in those survivors who had not graduated from college, were looking for work or unable to work, had an annual household income less than $20,000, did not have health insurance, or reported a major medical condition. The results of the multiple variable models evaluating the association between diagnostic and treatment variables and poor outcome (score < 40) on the summary scales or subscales of the SF-36 are shown in Tables V and VI, stratified for the two diagnostic categories. In survivors of Wilms tumor (Table V) , the final model included gender, age group at questionnaire, chest radiation, abdominal radiation, and pelvic radiation. After adjusting for the other variables in the model, no variable was associated significantly with a poor PCS score. However, females were more likely to have a poor MCS score than males (OR ¼ 1.67, 95% CI ¼ 1.1-2.5, P < 0.05). Female gender was also associated with a significantly increased risk of a poor outcome on the general health (OR ¼ 2.13, 95% CI ¼ 1.3-3.4, P < 0.05), vitality (OR ¼ 1.89, 95% CI ¼ 1.3-2.7, P < 0.05), and role function-emotional (OR ¼ 1.90, 95% CI ¼ 1.3-2.8, P < 0.05) subscales. Pelvic radiation was associated with poor outcome on the role function-physical subscale (OR ¼ 1.80, 95% CI ¼ 1.0-3.3, P < 0.05).
In survivors of neuroblastoma (Table VI) , the final model included gender, age at questionnaire, survival time, abdominal radiation, spinal radiation, pelvic radiation, and laminectomy. As with Wilms tumor, no variable was associated with a poor PCS score. Again, females were more likely to have a poor MCS score than males (OR ¼ 1.66, 95% CI ¼ 1.0-2.8, P < 0.05). Female gender was also associated with a significantly increased risk of a poor outcome on the role function-physical (OR ¼ 2.07, 95% CI ¼ 1.1-4.0, P < 0.05), general health (OR ¼ 2.10, 95% CI ¼ 1. Odds ratio significant at P 
DISCUSSION
This follow-up study adds to the literature on health outcomes among long-term survivors of Wilms tumor and neuroblastoma by evaluating HRQL. In this population of young adults who were treated for cancer at a very young age, we found no evidence for significant deficits in HRQL measures representing physical well being or functioning. However, there is a clear pattern of poor emotional health evident in both diagnostic groups. Survivors scored considerably below population norms on the MCS scale of the SF-36, a composite measure reflecting performance on the vitality, social function, role-emotional, and mental health subscales. This is of particular concern because scores below 42 on this summary scale have been shown to have high sensitivity and specificity for diagnoses of depression in other studies [30] . Although women consistently scored lower than men on these measures, the pattern of lower scores was evident for both sexes. Poorer HRQL outcomes amongst females have been reported in many studies of both acute and chronic illness [31] [32] [33] , and female survivors of childhood cancer have been demonstrated previously to have a higher likelihood of adverse health status [25] and poorer HRQL than males [34] . In addition to female gender, several other sociodemographic factors correlated with overall worse outcome on one or more measures of HRQL. These included patients who were unemployed or looking for work, those with lower annual incomes, and those who had not graduated from college. Importantly, no specific disease characteristics or treatment exposures were predictive of poorer performance on the MCS subscale for either diagnosis. Thus, treatment intensity is not predictive of poorer emotional health and all survivors should be evaluated for this adverse outcome regardless of the severity of their initial cancer. These findings may be important to primary care physicians, who are the most likely health care providers to have regular contact with this population and may be most able to screen for depression or anxiety during routine care visits.
We observed no difference on any measure of HRQL between diagnostic groups. This might be attributable to two factors. First, the survival of patients with high-risk neuroblastoma is poor [35] , resulting in a relative absence of survivors of high-stage disease. Most survivors of high-risk neuroblastoma experience one or more long-term complications of their disease or therapy, with almost one third reporting severe or life-threatening complications [19] . The most common of these are hearing loss, hypothyroidism and acute ovarian failure. Although stage information was not captured in the CCSS database, over 40% of the neuroblastoma survivors in the current cohort did not receive any chemotherapy, suggesting a high proportion of patients with lower stage disease who are less likely to develop long-term adverse effects. Alternatively, the absence of a difference in HRQL between the two groups in this study may be explained by the historical use of more aggressive multi-modal therapies in many patients with Wilms tumor treated in prior eras. This might serve to increase their risk of long-term morbidity compared to contemporary cohorts. Almost two-thirds of Wilms tumor survivors in this cohort received radiotherapy and over one-third received anthracycline chemotherapy. These treatment modalities may increase the risk of the long-term sequelae of Wilms tumor therapy, including chronic renal failure [36] , congestive heart failure [37] , and second malignant neoplasms [7] , all of which would have impact on HRQL.
As expected, both radiation and surgery for local control of the primary tumor impacted on HRQL. Survivors of Wilms tumor who had received pelvic radiation were more likely to perform poorly on the role function-physical subscale of the SF-36. Pelvic radiation in patients with Wilms tumor has been linked to premature ovarian failure, infertility, adverse pregnancy outcomes [38] , and second malignant neoplasms [7] . Survivors of Wilms tumor who had received chest radiation were more likely to perform poorly on the social function and role function-emotional subscales of the SF-36. The use of chest radiation in Wilms tumor is usually reserved for patients with metastatic disease and this may reflect a group of survivors of higher risk disease. In survivors of neuroblastoma, a history of laminectomy was associated with an increased risk of poor performance on the role function-physical and bodily pain subscales of the SF-36. This might reflect the long-term consequences of this surgery which include scoliosis [19, 39] . However, children requiring laminectomy are more likely to have presented with spinal cord compression and thus, their poor performance might reflect residual neurologic compromise [40] . In addition, pelvic radiation was linked to poor general health in this group of patients. This study has some methodological limitations that should be considered when interpreting the results. First, although the SF-36 has been validated as a self-report instrument, data regarding current socioeconomic status and medical complications were generated similarly from self report, and were not validated externally. Second, incomplete participation in the CCSS by eligible patients may have biased our results if survivors with poorer HRQL were less (or more) likely to join the CCSS cohort and to continue to contribute information to the study. Although the response rate for the HRQL questionnaire was good amongst those survivors enrolled in the CCSS (75.4%), non-respondents tended to be of lower socioeconomic status than participants and were somewhat more likely to have reported a major medical condition. These differences, not uncommon in health outcome studies, suggest caution be exercised when generalizing our findings to low social and economic strata. Third, the CCSS did not collect disease stage information because of a lack of consistency between staging systems used at different institutions. As a result, we cannot categorize survivors by disease stage, nor can we show the relationship between stage and HRQL outcomes. Finally, all members of this cohort were treated in the period between 1970 and 1986 and readers must be cautious in generalizing these results to patients treated on more contemporary protocols. Changes in the intensity of therapy, particularly in patients with Wilms tumor and those with low or intermediate risk neuroblastoma may result in different HRQL outcomes. Contemporary protocols often use lower doses of radiation and there have been improvements in the techniques and equipment used to deliver radiotherapy. There have been concomitant improvements in surgical techniques. Thus, patients treated on more recent protocols warrant separate investigation.
Pediatr Blood Cancer DOI 10.1002/pbc Despite differences in therapy, long-term survivors of Wilms tumor and neuroblastoma do not differ in their assessment of HRQL. Their physical well being and functioning is comparable to population norms, but they score significantly below these norms on measures of emotional health. Women and survivors in lower sociodemographic strata demonstrate the greatest risk of adverse outcomes. Health care providers must be sensitive to the risk for adverse outcomes in these vulnerable groups and institute appropriate screening and intervention.
